AbbVie nabs FDA's orphan drug tag for Humira in HS

AbbVie ($ABBV) is working to lessen its reliance on blockbuster Humira, which is already facing biosimilar competition in India. But it's also working to broaden the drug's label, and on that front, it got a boost from the FDA on Friday. The arthritis and psoriasis drug grabbed the agency's orphan drug designation for its cash cow for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS), a chronic inflammatory skin disease. Release | More